Literature DB >> 2145753

Experimental studies of the physiologic properties of technetium-99m agents: myocardial transport of perfusion imaging agents.

D J Meerdink1, J A Leppo.   

Abstract

The physiologic properties of new technetium-99m-labeled myocardial imaging agents (Tc-99m sestamibi, an isonitrile; and Tc-99m teboroxime, a boronic acid adduct of technetium dioxime) are discussed and compared to thallium-201 (Tl-201). Studies with isolated hearts, subcellular fractions and cell cultures indicate that Tc-99m sestamibi, Tc-99m teboroxime and Tl-201 do not share common transport or sequestration mechanisms. Although peak Tc-99m sestamibi myocardial extraction over time is about half that of Tl-201 at equivalent coronary blood flows, the amount of Tc-99m sestamibi that remains in the heart is similar to that of Tl-201 because of its higher retention efficiency. The high retention efficiency for Tc-99m sestamibi also results in minimal redistribution. In contrast, Tc-99m teboroxime myocardial extraction is higher than that of Tl-201, but its retention is less efficient, resulting in relatively rapid washout characteristics which may quickly result in tracer redistribution. During reperfusion after a no-flow period, Tc-99m sestamibi extraction and retention increase, but for Tc-99m teboroxime and Tl-201 these values tend to decrease. All tracers show adequate transport characteristics for perfusion imaging, and differences in transport and retention should lead to the development of new clinical protocols.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2145753     DOI: 10.1016/0002-9149(90)90606-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Diagnostic and prognostic applications for vasodilator stress myocardial perfusion imaging and the importance of radiopharmaceutical selection.

Authors:  R C Hendel
Journal:  J Nucl Cardiol       Date:  2001 Jul-Aug       Impact factor: 5.952

2.  Technetium-99m sestamibi scintigraphy for the assessment of lower extremity ischaemia in peripheral arterial disease.

Authors:  L Bajnok; B Kozlovszky; J Varga; J Antalffy; S Olvasztó; T Fülöp
Journal:  Eur J Nucl Med       Date:  1994-12

3.  Myocardial uptake of thallium 201 and technetium 99m-labeled sestamibi after ischemia and reperfusion: comparison by quantitative dual-tracer autoradiography in rabbits.

Authors:  H Weinstein; C P Reinhardt; J F Wironen; J A Leppo
Journal:  J Nucl Cardiol       Date:  1994 Jul-Aug       Impact factor: 5.952

4.  Dipyridamole technetium 99m sestamibi myocardial tomography as an independent predictor of cardiac event-free survival after acute ischemic events.

Authors:  D D Miller; H G Stratmann; L Shaw; B R Tamesis; M D Wittry; L T Younis; B R Chaitman
Journal:  J Nucl Cardiol       Date:  1994 Jan-Feb       Impact factor: 5.952

5.  Comparison between exercise and trans-oesophageal atrial pacing in patients with coronary artery disease: technetium-99m methoxy isobutyl isonitrile simultaneous evaluation of ventricular function and myocardial perfusion.

Authors:  A Cuocolo; M Santomauro; L Pace; L Celentano; A Nappi; E Nicolai; M Chiariello; M Salvatore
Journal:  Eur J Nucl Med       Date:  1992

6.  Positron emission tomography myocardial perfusion and glucose metabolism imaging.

Authors:  Josef Machac; Stephen L Bacharach; Timothy M Bateman; Jeroen J Bax; Robert Beanlands; Frank Bengel; Steven R Bergmann; Richard C Brunken; James Case; Dominique Delbeke; Marcelo F DiCarli; Ernest V Garcia; Richard A Goldstein; Robert J Gropler; Mark Travin; Randolph Patterson; Heinrich R Schelbert
Journal:  J Nucl Cardiol       Date:  2006-11       Impact factor: 3.872

7.  Myocardial clearance of technetium-99m-teboroxime in reperfused injured canine myocardium.

Authors:  David R Okada; Gerald Johnson; Robert D Okada
Journal:  EJNMMI Res       Date:  2014-08-01       Impact factor: 3.138

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.